Dive into the latest data from the RATIONALE-315 trial presented at ESMO 2024, evaluating event-free survival (EFS) and overall survival (OS) with neoadjuvant tislelizumab plus chemotherapy followed by adjuvant tislelizumab in patients with resectable non-small cell lung cancer (NSCLC).
???? Stay updated with cutting-edge immunotherapy research in thoracic oncology.
#RATIONALE315 #ESMO2024 #NSCLC #Tislelizumab #LungCancer #Immunotherapy #CancerTrials
???? Stay updated with cutting-edge immunotherapy research in thoracic oncology.
#RATIONALE315 #ESMO2024 #NSCLC #Tislelizumab #LungCancer #Immunotherapy #CancerTrials
- Category
- Oncology

Be the first to comment